Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Organogenesis Holdings Inc. is a publicly traded regenerative medicine company that develops, manufactures, and commercializes bioactive products for the repair and regeneration of soft tissue. The company operates primarily within the advanced wound care and surgical and sports medicine industries, focusing on biologically derived therapies designed to promote healing by leveraging the body’s natural regenerative processes. Its core offerings are used in the treatment of chronic and acute wounds, as well as in musculoskeletal and surgical applications.
The company’s principal revenue drivers are its commercially marketed wound care and surgical biologic products sold primarily to hospitals, wound care centers, and physician offices. Organogenesis is recognized for its expertise in living cell-based and acellular biologic technologies, which differentiate it from traditional wound care solutions. Founded in 1985, the company evolved from a research-focused biotechnology firm into a scaled commercial organization, with a major inflection point occurring after the acquisition of Apligraf® and Dermagraft® from Stryker Corporation in 2019, significantly expanding its market presence and revenue base.
Business Operations
Organogenesis conducts business through two primary operating segments: Advanced Wound Care and Surgical & Sports Medicine. The Advanced Wound Care segment generates the majority of revenue and includes products used to treat diabetic foot ulcers, venous leg ulcers, and other chronic or complex wounds. Key products in this segment include Apligraf®, Dermagraft®, and PuraPly® product lines, which are sold mainly in the United States and reimbursed through established payer pathways.
The Surgical & Sports Medicine segment focuses on regenerative solutions for musculoskeletal injuries and surgical applications, including biologic allografts and flowable matrices. Products in this segment are marketed to orthopedic surgeons, sports medicine specialists, and hospitals. Organogenesis controls proprietary manufacturing processes for both living-cell and acellular biologics and operates regulated manufacturing facilities. The company does not publicly disclose material joint ventures; its operations are primarily conducted through wholly owned subsidiaries, including Organogenesis Inc., which houses its core commercial and manufacturing activities.
Strategic Position & Investments
Organogenesis’ strategy centers on expanding adoption of its existing commercial products while investing in next-generation regenerative technologies. Growth initiatives include increasing penetration in U.S. wound care clinics, expanding physician education, and leveraging clinical evidence to support broader reimbursement coverage. The acquisition of Apligraf® and Dermagraft® remains the most significant strategic investment in the company’s history, materially strengthening its competitive position in the advanced wound care market.
The company continues to invest in research and development aimed at expanding indications for existing products and developing new biologic therapies. While Organogenesis evaluates selective acquisitions and in-licensing opportunities, publicly available disclosures indicate that organic growth and lifecycle management of its current portfolio remain the primary strategic focus. Data inconclusive based on available public sources regarding any large pending acquisitions or material equity investments beyond disclosed product portfolio expansions.
Geographic Footprint
Organogenesis is headquartered in Canton, Massachusetts, and conducts the vast majority of its commercial operations in the United States, which represents its primary revenue-generating market. Manufacturing and quality operations are also U.S.-based, supporting compliance with domestic regulatory and reimbursement requirements.
International activity is limited and not a significant contributor to consolidated revenue based on publicly available disclosures. While some products may be distributed outside the United States through select channels, the company’s strategic and operational focus remains concentrated in North America, with no material manufacturing or commercial hubs disclosed in other regions.
Leadership & Governance
Organogenesis is led by an executive team with extensive experience in regenerative medicine, medical devices, and life sciences commercialization. Leadership emphasizes disciplined growth, clinical evidence generation, and operational scalability within regulated healthcare markets. The company operates under a shareholder-aligned governance structure typical of U.S.-listed life sciences firms.
Key executives include:
- Gary S. Gillheeney, Sr. – President and Chief Executive Officer
- Lori Guthrie – Chief Financial Officer
- John Tighe – Chief Operating Officer
- David McQuillan – Chief Commercial Officer
- Timothy J. Hennessey – General Counsel and Secretary
The leadership team’s stated strategic vision, as reflected in public filings and earnings communications, centers on sustainable revenue growth, disciplined cost management, and continued innovation in regenerative medicine therapies.